The FDA assessed the protection and usefulness of atidarsagene autotemcel dependant on knowledge from 37 small children who been given atidarsagene autotemcel in two single-arm, open-label clinical trials As well as in an expanded entry plan.[7] Young children who obtained therapy with atidarsagene autotemcel were when compared to untreated childre